2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4180 Immune effector Cell–Associated toxicities after talquetamab bridging and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Adam Duca, BS, Robert Norberg2, Omkar Bhabad3, Larry Grullon-Polanco, N/A4, Myles Kim, PhD5, Emily C. Merritt6, Gabriel De Avila7, Omar Alexis Castaneda Puglianini, MD8, Hien Liu, MD9, Melissa Alsina, MD10, Taiga Nishihori, MD11, Kenneth H. Shain, MD, PhD12, Rachid Baz, MD13, Frederick L. Locke, MD14, Elizabeth Hyjek, MD15, Doris K. Hansen, MD16, Ariel Grajales-Cruz, MD17, Ciara Louise L Freeman, MD, PhD18
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States, Nova Southeastern University, Fort Lauderdale, Florida, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Background: Talquetamab, a GPRC5D-directed bispecific antibody, is increasingly being used as bridging therapy before BCMA-directed Chimeric Antigen Receptor T-cell (CART) therapy in relapsed/refractory multiple myeloma (RRMM), including ciltacabtagene autoleucel (cilta-cel). Recent clinical experience suggests that talquetamab can substantially reduce disease burden before CART infusion and may be associated with low rates of severe early cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Whether talquetamab bridging definitively reduces non-ICANS immune effector cell (IEC) associated toxicities (immune effector cell–associated nerve palsies (IEC-NP), parkinsonism (IEC-PKS), and enterocolitis (IEC-EC) despite achieving improved disease control is uncertain.

Methods: This single-center analysis included 73 consecutive patients with RRMM who received talquetamab bridging prior to cilta-cel infusion between March 2024 and June 2026. Disease response from apheresis to pre-lymphodepletion (pre-LD) was assessed by IMWG criteria using serum M-protein when measurable, otherwise involved free light chains or marrow. Post cilta-cel CRS and ICANS were manually adjudicated per ASTCT criteria (Lee et al 2019). Baseline disease burden, pre-LD inflammatory markers (ferritin, CRP), marrow plasma cell percentage, soluble BCMA (sBCMA) when available, active extramedullary disease (EMD), and delayed neurologic/gastrointestinal toxicities (with onset timing) were captured. Given the small number of events, comparisons between patients with and without IEC-associated toxicities used Wilcoxon rank-sum or Fisher exact testing and were interpreted descriptively. All patients had at least 30 days of follow-up; median follow-up from apheresis was 12.7 months (range 2.3–30.0).

Results: Talquetamab bridging was initiated a median of 9 days after apheresis, and a median of 43 days (range 21 -101) prior to cilta-cel infusion. The cohort was heavily pretreated: 100% triple-class exposed, 87.7% anti-CD38 refractory, 13.7% penta-refractory, 6.8% prior BCMA-directed therapy; prior receipt of median 4 prior lines; 49.3% had prior autologous transplant. Talquetamab bridging was associated with marked disease reduction: median marrow plasma cell involvement decreased from  45% at apheresis to 1% pre-LD, 69.7% (46/66) had <5% pre-LD; and median sBCMA declined from 471.21 ng/mL to 31.5 ng/mL. Early CART toxicity was favorable: CRS occurred in 61.6% and ICANS in 9.6%, with no grade ≥3 CRS or ICANS. Delayed IEC-associated toxicities occurred in 11/73 (15.1%). IEC-NP in 9 (12.3%) with median onset day 24 (range D12–D48); most often affecting CN VII (8/9); all 9 received corticosteroids, 8 received IVIG; and 8 had complete resolution at time of last follow up. One patient developed IEC-PKS (1.4%, day 71, with concomitant IEC-NP), and IEC-EC in 3/73 (4.1%). These events were seen even in patients with effective bridging response, rather than being limited to those with persistent disease. Compared with unaffected patients, those with IEC-associated toxicities more often had <5% marrow plasma cell involvement before CART (81.8% [9/11] vs 67.3% [37/55]), had similar rates of active EMD (27.3% vs 30.6%), and had lower median pre-LD ferritin (155 vs 300 ng/mL) and sBCMA when available (17.8 vs 35.29 ng/mL; available in 7/11 affected patients). CRS occurred in all 11 patients with IEC-associated toxicities, all grade 1, compared with 54.8% of unaffected patients (Fisher p=0.005). These comparisons should be interpreted descriptively due to the small number of events.

Conclusions: Talquetamab bridging can achieve highly effective disease control and a favorable early CART toxicity profile, yet IEC-associated toxicities; IEC-NP, IEC-PKS and IEC-EC still occurred in 15.1% of patients. Events occurred despite effective debulking and were not associated with obvious differences in pre-CART disease burden or inflammatory markers in this descriptive analysis. Clinicians should continue to monitor closely for delayed neurologic and gastrointestinal IEC-associated toxicities after cilta-cel, even when talquetamab bridging produces a deep pre-infusion response.

Adam Duca, BS: No relevant conflicts of interest to declare.